• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
PharmaPoint: Dry Eye Syndrome - Spain Drug Forecast and Market Analysis to 2022 - Product Image

PharmaPoint: Dry Eye Syndrome - Spain Drug Forecast and Market Analysis to 2022

  • ID: 2641002
  • May 2013
  • Region: Spain
  • 77 pages
  • GlobalData

PharmaPoint: Dry Eye Syndrome - Spain Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, “PharmaPoint: Dry Eye Syndrome - Spain Drug Forecast and Market Analysis to 2022”. Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation. The most common symptoms of DES are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities. In the elderly population, it is the most common reason for seeking eye care, and this is expected to increase exponentially with an aging demographic.

The DES market in Spain is projected to grow substantially during the forecast period. During the forecast period, the primary growth drivers of the DES market in Spain will be the launch of the EU’s first prescription product for DES, as well as a rapidly increasing population of DES patients.

Scope

- Overview of the READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Classification
3.1.4 Prognosis
3.1.5 Quality of Life
3.2 Symptoms
4 Disease Management
4.1 Overview
4.1.1 Diagnosis Overview
4.1.2 Treatment Guidelines
4.1.3 Treatment Overview
4.2 Spain
4.2.1 Diagnosis
4.2.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles – Major Brands
5.3.1 Restasis (cyclosporine 0.05% ophthalmic emulsion)
5.3.2 Additional Therapies
6 Opportunity and Unmet Need
6.1 Overview
6.2 Diagnostic tests are not specific enough to identify subgroups of patients
6.3 Frequent dosing and side effects limit compliance
6.4 Lack of physician and patient awareness
6.5 Trial design may be a factor in so few drugs being approved
6.6 Unmet Needs Gap Analysis
6.7 Comprehensive method for measuring dry eye signs and severity levels
6.8 Increase treatment rates among milder forms of the disease
7 Pipeline Assessment
7.1 Overview
7.2 Promising drugs in clinical development
7.2.1 Lifitegrast
7.2.2 CF-101
7.2.3 Cyclokat
8 Market Outlook
8.1 Spain
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed DES patients
9.4.2 Percent Drug-treated Patients
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Generic Erosion
9.5 Physicians and Specialists Included in this Study
9.6 About the Authors
9.6.1 Author
9.6.2 Global Head of Healthcare
9.7 About Us
9.8 Contact Us
9.9 Disclaimer

1.1 List of Tables
Table 1: Symptoms of Dry Eye Syndrome
Table 2: Treatment Guidelines for Dry Eye Syndrome
Table 3: Commonly Prescribed Drugs for Dry Eye Syndrome by Class in the Global Markets, 2012
Table 4: Leading Treatments for Dry Eye Syndrome, 2012
Table 5: Product Profile – Restasis
Table 6: Restasis SWOT Analysis, 2012
Table 7: Summary of Minor Drug Classes, 2012
Table 8: Overall Unmet Needs – Current Level of Attainment
Table 9: Clinical Unmet Needs – Gap Analysis, 2012
Table 10: Dry Eye Syndrome – Phase Pipeline, 2012
Table 11: Comparison of Therapeutic Classes in Development for Dry Eye Syndrome, 2012
Table 12: Product Profile – Lifitegrast
Table 13: Lifitegrast SWOT Analysis, 2012
Table 14: Product Profile – CF101
Table 15: CF101 SWOT Analysis, 2012
Table 16: Product Profile – Cyclokat
Table 17: Cyclokat SWOT Analysis, 2012
Table 18: Sales Forecasts ($m) for Dry Eye Syndrome in Spain, 2012–2022
Table 19: Key Events Impacting Sales for Dry Eye Syndrome in Spain, 2012–2022
Table 20: Spain, Dry Eye Syndrome Market – Drivers and Barriers, 2012–2022
Table 21: Key Launch Dates
Table 22: Key Patent Expiries

1.2 List of Figures
Figure 1: Dry Eye Syndrome – Disease Etiology
Figure 2: Tear Film in Normal Eye and Dry Eye
Figure 3: Sequence of Diagnostic Tests Used to Diagnose Dry Eye Syndrome
Figure 4: Delphi Panel Treatment Recommendations for Dysfunctional Tear Syndrome Without Lid Margin Disease, 2006
Figure 5: Delphi Panel Treatment Recommendations for Dysfunctional Tear Syndrome With Lid Margin Disease and Abnormal Tear Distribution, 2006
Figure 6: Treatment Recommendations for Dry Eye Syndrome from the Management and Therapy Subcommittee, Dry Eye Workshop, 2007
Figure 7: American Academy of Ophthalmology Preferred Practice Pattern for Dry Eye, 2011
Figure 8: Competitive Assessment of Late-Stage Pipeline Agents in Dry Eye Syndrome, 2012–2022
Figure 9: Sales for Dry Eye Syndrome in Spain by Drug Class, 2012–2022

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos